Organophosphate Insecticides (OPC)
Organophosphate Insecticides (OPC)
Organophosphate Insecticides (OPC)
Pathophysiology
Inhibition of cholinesterase enzymes
accumulation of acetylcholine at CNS,
muscarinic and nicotinic receptors classic
cholinergic syndrome
Pathophysiology
Inhibits cholinesterase
True cholinesterase
RBC membranes
Nervous tissue
Skeletal muscle
Plasma cholinesterase
Serum
Liver
Pancreas
Heart
Brain
Aging
Permanent, irreversible binding to
cholinesterase.
*the enzyme is permanently destroyed,
and would take several weeks to
resynthesize
Clinical manifestations of OPC toxicity
Dependent on:
Type of agent
Quantity absorbed
Type of exposure
Variety
Systems (CNS, muscarinic, nicotinic)
Onset
Most rapid: inhalation
Least: transdermal absorption
A 52 y old man presents with several days of diarrhea
followed by the sudden onset of confusion, frequent
vomiting, loss of bowel and bladder control,
rhinorrhea, cough, excessive tearing, and tremors. He
had profuse sweating, but no fever or chills.
Physical examination: Temperature 35.6 c, pulse
94/min, respiration 18/min, blood pressure 144/82,
mildly constricted pupils, chest scattered rhonchi, skin
diaphoretic. Neuromuscular: alert oriented to persons
and place diffuse weakness and tremors
I- Cholinergic syndrome
A- Central (CNS) manifestations
Vertigo, confusion , convulsions and coma
Due to inhibition of brain A.Ch.E
Brain cholinesterase coincides with true
cholinesterase found in RBCs
B- Muscarinic manifestations
1- Respiratory
Bronchospasm and wheezes
Bronchorrhea
Pulmonary edema
2- CVS
Bradycardia
Hypotension
Arrhythmias
3- GIT
Salivation
Vomiting
Diarrhea
4- Eye
Lacrimation
Pin point pupils
5- Skin
Sweating
Subnormal temperature
6- Urination
C- Nicotinic manifestations
1- Myoneural junction
Fasciculations and twitches
Muscle cramps
Muscle weakness then paralysis
2- Sympathetic ganglia
Tachcardia and hypertension
3- Adrenal medulla
Release of catecholamines
II- Cardiotoxic effects
III- Intermediate syndrome
Manifestations
Weakness of motor cranial nerves, respiratory, neck and
proximal limb muscles with subsequent respiratory
muscle paralysis so the patient may need mechanical
ventilation.
Onset
It usually occurs within the first 2 -5 days after acute
poisoning and resolution of cholinergic syndrome
Early treatment with Ch E reactivators may prevent the
intermediate syndrome
IV- Delayed neuropathy
It usually occurs 14 - 21 days after exposure to some OP
compounds even after a skin contact.
It is mixed sensory-motor neuropathy
It usually begins in the legs, first causing burning or
tingling sensations, then weakness of the lower legs and
feet. The thighs and arms also become involved.
It is due to nerve demyelination and is usually
permanent.
Investigations
1- ECG and cardiac monitoring
2- Level of true and pseudo cholinesterase enzymes
Levels of:
50 % of normal: mild toxicity (sub clinical)
30 - 40% of normal: mild to moderate toxicity
Less than 20 to 25 % of normal: severe toxicity
3- ABGs
4- Electrolytes
Differential Diagnosis
1. Carbamates
2. Drugs causing miosis e.g. opiates,
phenothiazines
3. Pontine hemorrhage
4. Gastroenteritis
5. Mushrooms
Treatment
I- Stabilization of the patient (ABCD)
II- Decontamination
A- Dermal exposure
Removal of contaminated clothes
Wash the skin using tap water
If the hair is still smelly it may be cut to avoid relapses
from continuous absorption.
B- Oral ingestion
Induction of emesis should be avoided
Gastric lavage after endotracheal intubation with cuffed
tube
Activated charcoal
III- Antidotes
A. Atropine
Actions
It antagonizes muscarinic but not nicotinic manifestations.
It improves CNS depression
Dose
Adult: 1 - 2 mg IV
Pediatric: 0.01 mg/kg
repeated till
Dryness of secretions
Relief of bronchospasm and wheezes.
Do not rely on pupil size
B. Oximes (cholinesterase reactivators)
Dose:
Pralidoxime (PAM)
Obidoxime (Toxogonin)